Inaugural Open Access Issue of SLAS Discovery Paves Way for 2022

Oak Brook, IL (February 3, 2022) – Volume 27, Issue 1 of SLAS Discovery is the first issue to be published Open Access in partnership with SLAS’s new publisher, Elsevier.

Historically, SLAS Discovery focused primarily on automation, screening, and its application to drug discovery. Responding to the evolution of science, the scope of publication broadened to include scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies), biomarker discovery, assay development, virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME), lead generation/optimization, chemical biology, and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics).

SLAS is committed to continuing to deliver high-quality research into 2022 and beyond. Special Issues and Collections focused on cutting edge topics in rapidly moving fields will continue to be published into the new year. Upcoming issues include “3D Cell Culture Approaches of Microphysiologically Relevant Models,” as well as an “Early Career Scientist Showcase.” SLAS Discovery, “will continue to respond as necessary to the changing environment for the benefit of our readers and the scientific community,” according to Ally Jump and Robert M. Campbell, Ph.D., Editor-in-Chief, in the January issue editorial. “In 2022, we are opening our content up to the world, free of access or subscription fees, knowing that it will propel our science forward and enable us to progress even more quickly than before.”

In addition to the editorial, this issue of SLAS Discovery also includes seven articles of original research and one review:

• Fragment-based screening: A new paradigm for ligand and target discovery
• Identification of potent small molecule inhibitors of SARS-CoV-2 entry  
• Using measures of metabolic flux to align screening and clinical development: Avoiding pitfalls to enable translational studies
• Deep learning Image Analysis of High-Throughput Toxicology Assay Images
• Detection and impact of hypoxic regions in multicellular tumor spheroid cultures formed by head and neck squamous cell carcinoma cells lines
• Identification of positive modulators of TRPM5 channel from a high-throughput screen using a fluorescent membrane potential assay
• High-throughput screening for identifying acetylcholinesterase inhibitors: Insights on novel inhibitors and the use of liver microsomes
• High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes

Access to this issue of SLAS Discovery is available at https://www.sciencedirect.com/journal/slas-discovery/vol/27/issue/1

For more information about SLAS and its journals, visit https://www.slas.org/publications/slas-discovery/

*****

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.918. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).

###